


## Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer



Stephanie Gomez<sup>1,2,3</sup>, Olivia L. Cox<sup>1,2</sup>, Reddick R. Walker III<sup>1,2,3</sup>, Uzma Rentia<sup>1,2</sup>, Melissa Hadley<sup>1,2</sup>, Elisa Arthofer<sup>1,2</sup>, Noor Diab<sup>1,2</sup>, Erin E. Grundy<sup>1,2,3</sup>, Tomas Kanholm<sup>1,2,3</sup>, James I. McDonald<sup>1,2</sup>, Julie Kobyra<sup>1,2</sup>, Erica Palmer<sup>1,4</sup>, Satish Noonepalle<sup>4</sup>, Alejandro Villagra<sup>4</sup>, David Leitenberg<sup>2,5</sup>, Catherine M. Bollard<sup>1,2,6</sup>, Yogen Sauntharajah<sup>7</sup>, Katherine B. Chiappinelli<sup>1,2,3</sup>

- DNMTi and Adar1 knockdown induces type I interferon-driven changes in the tumor immune microenvironment, specifically an increase in CD8+ T cells and natural killer cells
- This immunogenic combination results in a significant increase in survival and decrease in tumor burden in an aggressive model of late-stage ovarian cancer